Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul 19:6:211.
doi: 10.1186/1752-1947-6-211.

Leukemoid reaction in a patient with adenocarcinoma of the lung: a case report

Affiliations

Leukemoid reaction in a patient with adenocarcinoma of the lung: a case report

Hendrik Riesenberg et al. J Med Case Rep. .

Abstract

Introduction: Lung cancers are characterized by high incidence, prevalence and mortality. They may be associated with numerous paraneoplastic syndromes. Mild leukocytosis is not rare. The case described here, however, is of a female patient with adenocarcinoma of the lung who developed extreme leukocytosis at over 140,000 cells/μL. Descriptions of such leukemic forms of lung cancer are few and far between in the literature. In our case, the complete hematological diagnostic investigation, which included cytological, immunocytological, cytogenetic, histological and molecular genetic tests of the bone marrow (mutation analyses of BCR-ABL and JAK2), was accompanied for the first time by a molecular genetic workup of the primary tumor for epidermal growth factor receptor and K-RAS gene mutations.

Case presentation: We present the medical case of a 51-year-old female Caucasian patient, who was diagnosed with a poorly differentiated stage IV (International Union Against Cancer staging) adenocarcinoma of the lung. While undergoing treatment, our patient developed extreme leukocytosis, for which, despite extensive diagnostic tests, no infection-related or hematological cause could be identified. The tumor proved to be highly resistant to treatment. Our patient died only five months after the initial diagnosis.

Conclusion: A leukemoid course can most likely be interpreted as the paraneoplastic production of hematopoietic growth factors. Despite the absence of a verified primary hematological origin, this possibility should always be investigated in all patients in a comparable situation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Primary lesion. Pulmonary tumor in the right hilar region with a diameter of 2.3cm in close proximity to the upper lobe and encircling the right main bronchus.
Figure 2
Figure 2
Peripheral blood smear. Extreme leukocytosis with largely normal differentiation and complete maturation (neutrophils 85%, lymphocytes 1%, monocytes 2%, eosinophils 0%, basophils 1%, metamyelocytes 6%, myelocytes 5%).
Figure 3
Figure 3
Bone marrow cytology. Massively increased and left-shifted granulopoiesis up to the myeloblasts with displaced erythropoiesis and normal megakaryopoiesis, as can typically develop on stimulation with granulocyte colony-stimulating factor (myeloblasts 4%, promyelocytes 12%, myelocytes 15%, metamyelocytes 7%, band cells 13%, segmented neutrophils 31%, proerythroblasts 2%, erythroblasts 16%, lymphocytes 2%).

References

    1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005;16:481–488. doi: 10.1093/annonc/mdi098. - DOI - PubMed
    1. National Cancer I. Surveillance epidemiology and end results. http://seer.cancer.gov.
    1. McKee LC Jr. Excess leukocytosis (leukemoid reactions) associated with malignant diseases. South Med J. 1985;78:1475–1482. doi: 10.1097/00007611-198512000-00018. - DOI - PubMed
    1. Griesinger F, Metz M, Trümpler L, Schulz T, Haase D. Secondary leukaemia after cure for locally advanced NSCLC: alkylating type secondary leukaemia after induction therapy with docetaxel and carboplatin for NSCLC IIIB. Lung Cancer. 2004;44:261–265. doi: 10.1016/j.lungcan.2003.11.015. - DOI - PubMed
    1. Matsuo K, Kiura K, Tabata M, Uchida A, Hotta K, Niiya D, Kubonishi S, Ogino A, Fujiwara Y, Nakajima H, Shinagawa K, Ishimaru F, Ueoka H, Tanimoto M. Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution. Am J Hematol. 2006;81:349–354. doi: 10.1002/ajh.20569. - DOI - PubMed